All In Biotech

Drug Trial Radar · NCT06499350

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Dec 1, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

  • FC084CSA+Tislelizumab combination (dose escalation)Drug

    Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy

  • RP2D of FC084CSA+Tislelizumab combination (dose expansion)Drug

    RP2D of FC084CSA+fixed dose Tislelizumab combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 8 months
  2. Determine the Recommended Phase 2 Dose (RP2D)Time frame: Approximately 8 months
  3. Determine dose-limiting toxicity (DLT)Time frame: 21 days after first dose
  4. Objective response rate (ORR)Time frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.